Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Adderall XR Prescribers (US)(?)

Council Members in this Study Group: 79

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Daniel Wynn, MD, Director, Clinical Research, Consultants In Neurology Ltd.Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.

Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...

Lawrence Ginsberg, MD
President
Red Oak Psychiatry Associates, P. A.

Lawrence Ginsberg, MD, is President and CEO of Red Oak Psychiatry Associates, PA, a multidisciplinary mental health group in Houston, Texas. Dr. Ginsberg's research interests include psychopharmacology, addiction medicine, and forensic psychiatry. His areas of clinical expertise are attention deficit...

Louis Sanfilippo, MD
Psychiatrist
Louis Sanfilippo, MD

Louis Sanfilippo, MD, is an Assistant Clinical Professor of Psychiatry at Yale School of Medicine and in private practice. He has served management and scientific advisory roles for Cenestra Health, a biotech company focused on developing empirically validated nutraceutical products. Dr. Sanfilippo...

Amit Vijapura, MD
Owner
Amit Vijapura, MD

Amit Vijapura, MD, is a Private Practitioner in Psychiatry based in Florida. He has over 15 years of experience in the field and has expertise in depression, bipolar disorder, anxiety disorder, attention deficient disorder, and schizophrenia. Dr. Vijapura is board certified in Psychiatry and is also...

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
One Drug, Many Uses -- Mostly a Very Good Idea | 07-03-2008
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: Louis Sanfilippo, MD, Psychiatrist, Louis Sanfilippo, MD

‘One drug, many uses’ can make lots of sense clinically and commercially.   Seeking additional FDA indications for a specific drug has obvious business benefits:  greater revenue stream, improved branding, potentially longer market exclusivity, greater franchising potential of the drug...

Medicare's Perfect Storm: Losing Primary Care | 06-30-2008
Analysis of: Medicare fees to doctors fall Tuesday | news.yahoo.com
Author: GLG Expert Contributor

Your mother and father will not get the compassion and care when they call for medical help .   It will not be available.  Your family physician was financially forced to leave.

Lundbeck Reveals Mechanism of Action of its “Mixed Serotonin Modulator and Stimulator” Antidepressant LuAA21004 | 06-30-2008
Author: Louis Sanfilippo, MD, Psychiatrist, Louis Sanfilippo, MD

Lundbeck has now disclosed the mechanism of action of its “mixed serotonin modulator and stimulator,” albeit buried in a first quarter report.   Data on LuAA21004, Lundbeck’s lead antidepressant jointly in development with Takeda, was released at the Scandinavian College of Neuro-Psychopharmacology...

If you've done everything else, there is nothing else | 06-30-2008
Author: GLG Expert Contributor

We need to look to the cause of why we prescribe antipsychotics to patients with dementia.  We have very few tools to use and sometimes these drugs are a necessity.

We can't afford to practice the "best" medicine | 06-23-2008
Author: GLG Expert Contributor

This article clearly describes the Catch-22 in which most doctors, except for those employed by the large institutions, find themselves.  We cannot afford to practice the "best" medicine, and yet, if we could, we might well make fewer errors and make medical care for our patients more seamless. ...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Other Freestanding Healthcare Facility
  • Academic Institution*
  • Private/For-Profit Healthcare Research Entity

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • Director
  • Physician - Division Head
  • Partner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics